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Tissue Bank as a Source  
for Allogeneic Use
Tokiko Nagamura-Inoue and Fumitaka Nagamura
Abstract
Recently, umbilical cord blood (CB) has received attention as the allogeneic opti-
mum source for immunotherapies. More recently, the umbilical cord (UC) has been 
rapidly utilized as an abundant source of mesenchymal stromal cells (MSCs), which 
migrate toward the inflammatory and damaged tissue to subside the inflammation and 
support tissue repair. Both CB and UC can be provided “off-the-shelf” cell products 
for immunotherapies and regenerative medicine. As biomedical wastes, CB and UC 
can be obtained noninvasively without any risks to the donor. CB cells and UC-derived 
MSCs (UC-MSCs) also have higher proliferation potentials than other cells obtained 
from adult tissues. In addition, UC-MSCs are less immunogenic and have significant 
immunosuppressive ability. Several clinical trials with CB or UC-MSCs have been 
conducted based on these advantages. The establishment of a stable supply system 
of CB and UC-MSCs is critical now for their utilization in regenerative and immune 
cell therapies. We have thus established the cord blood/cord bank, “IMSUT CORD,” 
as a new type of biobank, to supply both frozen CB and UC tissues and derived cells 
for research and clinical uses. In this chapter, we will introduce the overall flow from 
collection to shipment and discuss several issues that need to be resolved in unrelated 
allogeneic stable supply system.
Keywords: cord blood, umbilical cord, mesenchymal stromal cells, immune cell 
therapy, regenerative medicine, biobank, explant method, large-scale expansion
1. Introduction
Umbilical cord blood (CB) has been utilized as a source of hematopoietic stem 
cells for three decades. It could potentially also serve as the optimum source of 
immune cells, such as mononuclear cells (MNC), regulatory T cells, NK cells, and 
mesenchymal stromal cells (MSCs) with or without genetic modifications, for 
immunotherapy and neurogenic regeneration in some cases. In addition, UB could 
be prepared as readily available products [1].
It is well-known that human mesenchymal stromal cells (MSCs) can be har-
vested from various tissues that include the bone marrow (BM) [2], cord blood 
(CB) [3], adipose tissue [4], placenta [5], and umbilical cord (UC) [6]. Recently, 
clinical trials using MSCs for various diseases have been conducted, and some 
of them were approved. The BM is considered the traditional source of MSCs, 
and the characteristics and applications of BM-derived MSCs (BM-MSCs) have 
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been studied in detail. However, the harvesting of these cells is associated with an 
invasive procedure, and it may cause hemorrhage, infection, and chronic pain. In 
addition, BM-MSCs exhibit accelerated senescence as the donors’ age [7].
On the other hand, both CB and UC are routinely discarded as medical waste. 
The harvesting of CB and UC-derived MSCs (UC-MSCs) is therefore noninvasive 
and painless. The CB drawn from the UC and placenta is well-known as the source of 
hematopoietic stem cells for CB transplantations. However, in this article, we focus on 
the CB as the source for immune cells and regenerative medicine, such as regulatory T 
cells (Treg), NK cells, MSCs, and so on. The UC is the conduit between the develop-
ing embryo and placenta and consists of two umbilical arteries and one umbilical 
vein buried in the Wharton’s jelly. UC-MSCs have the abilities of multipotency and 
self-renewal properties comparable or superior to MSCs derived from other tissues in 
some papers. For this reason, several private CB banks have begun to collect CB and 
UC. We have thus established the cord blood/cord bank, “IMSUT CORD”, as a new 
type of biobank, to supply both frozen UC tissues and master cells for research and 
clinical uses.
In this chapter, we will introduce the overall flow from collection to shipment 
as taking the example of IMSUT CORD and discuss several issues that need to be 
resolved in unrelated allogeneic off-the-shelf stable supply system at present.
2. Cord blood and umbilical cord collection
There are many public and private CB banks in the world, in which procedures 
are nearly standardized intended for hematopoietic stem cell transplantation 
(HSCT) as shown in Section 5. The procedures include informed consent acquisi-
tion from the mother, collection of CB, processing, storage, to shipment, which 
have been already established. In the case of UC bank for unrelated allogeneic 
uses, the International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) which issued ICH Q5A as the regulation 
of materials for biological products requires the second blood test from the baby’s 
mother, to deny viral infection in window period at delivery. Figure 1 shows the 
overall process of banking in the mother’s side. We deal with both CB and UC. In 
Figure 1. 
Overall flow from informed consent acquisition to shipment.
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the CB and UC collection hospitals, the purpose, overall process, private informa-
tion policy, the right to withdrawal, 6-month health check, and second blood test 
for the mother to confirm the negative study of infection are explained to the 
mother, and she gives written consent as the guardian of the baby. In addition to 
obtaining informed consent, questionnaires about medical history, genetic history 
of the baby donor’s family, and history for the mother’s communicable disease risk 
behavior are conducted to survey their health. The CB and UC are then collected, 
and the mother’s blood is tested for infections. These documentations and tests in 
CB bank can be referred to UC banking as well, although additional safety tests 
for UC banking shall be required strictly. UC-MSCs from one donor can be deliv-
ered and administered to many patients. Especially when the CB and UC passed 
the safety and some quality tests at clinical grade, the mother is asked to receive 
the blood test to make sure that all infection tests are negative in 6 months after 
delivery. These second tests are demanded by the Pharmaceuticals and Medical 
Devised Agency (PMDA) like the FDA and EMA, because it should be proven that 
the donor’s mother and baby were not in the window period of viral infections at 
delivery. On the other hand, bacterial contamination is also taken care because 
the baby and placenta with UC come out from nonsterile vagina. We collect UC in 
the case of a scheduled cesarean section to reduce the possibility of contamination 
due to the exposure to the vaginal bacterial/fungal flora.
CB and UC are then transported from the collection hospitals to the CB/UC 
bank under controlled and validated temperature. CB is transported at validated 
temperature range (2–25°C) to protect cell viability, and the UC is cooled at 2–10°C 
in our facility.
3. Cord blood processing
Among the processing methods to obtain nucleated cells from CB for hemato-
poietic stem cell transplantation, the hydroxyethyl starch (HES) centrifugation 
method (HES method) is the most efficient and common. The HES method 
originated from the New York Blood Center CB bank [8]. Recently, automated CB 
processing SEPAX® (GE Healthcare Life Sciences) [9] and AutoXpress Platform® 
(Cesca Therapeutics, Inc.) [10] have been developed. For CB cryopreservation, 
DMSO and Dextran 40 together with CB-plasma are used worldwide [8].
On the other hand, no processing method of fresh or frozen CB not for 
hematopoietic stem cell transplantation has been settled as standard. The use of 
mononuclear cells (MNCs) obtained by the Ficoll-Paque centrifugation method 
(Ficoll method) or cell sorting with antibody-conjugated magnetic beads might 
be a new candidate for further processing and culture method. CB processed by 
HES method resulted in whole nucleated cells including neutrophils, monocytes, 
lymphocytes, and nucleated red blood cells with some amount of red blood cells 
(RBC). The recovery rate of hematopoietic stem cells and mononuclear cells 
processed by HES method is superior to those by Ficoll method. That is why HES 
method is introduced by CB banks in the world [8]. However, neutrophils in 
the nucleated cells and residual RBC may cause the aggregation resulting in the 
difficulty of further processing, when the frozen and thawed cells are diluted 
with large volume of isotonic solutions such as medium. Only frozen-thawed 
CB nucleated cells can be diluted with dextran and albumin/saline solution 
[8]. On the other hand, frozen-thawed MNCs processed by Ficoll method does 
not require such a special solution and can be diluted with medium and PBS, 
although the recovery rate of MNCs from the fresh CB by Ficoll method is less 
than that by HES methods.
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MSCs derived from fresh CB are difficult to expand. Only one company, 
Medipost Co., Ltd., in Korea, has succeeded in expanding CB-derived MSCs. Their 
product, Cartistem®, has been approved by the Ministry of Food and Drug Safety 
in Korea for the treatment of osteoarthritis [11].
4. Umbilical cord processing
There are diverse procedures and culture methods for the isolation of MSCs 
from the various compartments of UC, such as Wharton’s jelly, veins, arteries, UC 
lining membrane, subamnion, and perivascular regions [12]. The isolation methods 
of MSCs from the Wharton’s jelly, vein, and arteries of UC are reported previously, 
although the marked differences were not found as far as the 10% fetal bovine serum 
(FBS) and α minimum essential medium (MEM) [13]. There are several papers to 
obtain MSCs from whole UC versus Wharton’s jelly [14] or different parts of the 
same UC [15], but we suggest that to process from whole UC seems sufficient and 
simple for further processing [15]. Despite the wide range of isolation and culture 
procedures, the different groups seem to agree on the cryopreservation of UC tissue 
[16] and explant method [17] followed by the harvest of migrating cells from tissue. 
However, large-scale culture methods remain to be determined. Figure 2 shows the 
example of scheme of CB and UC collection and process and shipping to clinical use.
4.1 Cryopreservation of UC tissue
It is known that the UC tissue can be frozen in a cryoprotectant. This possibility 
of cryopreservation is the advantages of UC tissue for both clinical and research 
uses. The reasons of the advantages are:
1. UC tissue processing can be started after the donor’s health and infection statuses 
are confirmed well. This leads to initial cost-effectiveness because unnecessary 
works using inappropriate materials are eliminated. In addition, we can thaw a 
small amount of the UC to survey, before culturing MSCs in a large scale.
2. Storage of the tissues of origin allows us to keep traceability and to check the 
quality as the biological resources at a later date.
3. When new reagents or techniques were developed in the future, we can isolate 
novel cells from the cryopreserved UC tissues.
4. If the donor, the baby, has diseases that can be treated with autologous cells, 
including iPS cells or gene-modified cells, or autologous UC-MSCs, the cryo-
preserved UC tissues would be the appropriate source.
Several animal serum-free cryoprotectants containing 5–10% dimethyl sulfoxide 
(DMSO) are available. Whether the use of serum originating from animals, such 
as fetal bovine serum (FBS), is required, is critical, because it adds the risk of the 
transmission of zoonotic infections, immunological reactions, and additional regu-
latory issues [18]. There are several reports of cryopreservation of the UC tissue, 
using serum-free and xenogeneic animal-free (xeno-free) cryoprotectants. Ennis 
et al. introduced CryoStor CS10® (BioLife Solutions Inc., WA) for isolating human 
UC perivascular cells (HUPVCs). However, they did not show the comparative test 
results to those of fresh UC [19]. Roy et al. reported the cryopreservation of the 
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UC tissue in 10% DMSO and 0.2 M sucrose solution, but the cumulative cell yield 
derived from the frozen-thawed UC-MSCs in their solution was inferior to that of 
fresh UC-MSCs [20]. We previously reported the cryopreservation of UC tissue, 
with no impact on viability, using a serum- and animal origin-free cryoprotectant, 
STEM-CELLBANKER® [16]. We demonstrated that cells derived from UC cryopre-
served in this manner retained the phenotypic characteristics of MSCs, including 
the immunosuppressive activity in allogeneic mixed lymphocyte reactions, as well 
as differentiation potential. As shown in Figure 2, with the cryopreservation of UC 
tissue, UC processing might be altered.
4.2 Improved explant method
There are two major approaches after frozen-thawed UC tissue: explant and 
enzymatic digestion methods. Frozen-thawed UC tissue is manually minced into 
small fragments approximately 1–2 mm3 in size. Mincing is preferred to using a 
surgical scalpel or the use of an autologous mixer. These fragments are aligned and 
seeded regularly on a tissue culture-treated dish. After the tissue fragments attach 
to the bottom of the dish, culture media is added, slowly and gently in order not to 
detach the fragments [21–24]. Media is then refreshed every 3–7 days for 2–4 weeks 
until the fibroblast-like adherent cells reach 80–90% confluence. Subsequently, 
adherent cells and tissue fragments are rinsed once with PBS, detached using 
trypsin, and washed with media. The culture is then filtered to remove tissue frag-
ments. The disadvantage in the explant method is that tissue fragments often float 
in media, resulting in the poor recovery of cells. To protect the exfoliation of tissue 
fragments from the bottom of the culture dish, we introduced stainless steel mesh 
(Cellamigo®; Tsubakimoto Chain Co.) shown in Figure 2, No. 8. In this manner, 
we can plate source tissue more quickly and harvest more MSCs. In addition, the 
incubation time required to reach 80–90% confluence is reduced [17].
In the enzymatic digestion method, UC is minced into small pieces and 
immersed in the media containing enzymes such as collagenase, or a combination 
of collagenase and hyaluronidase with or without trypsin [21, 24–26]. The cells 
dissociated by the enzymes are then cultured until they reach full confluence. 
Figure 2. 
IMSUT CORD scheme of CB and UC from collection to shipping for clinical use.
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However, the digestion method is costly and time-consuming and may result in 
decreased cell viability due to lytic activity and varying sensitivity of the cells to 
collagenase. In addition, the initial harvested cells include more of the other types 
of cells compared with that harvested using the explant method.
4.3 Large-scale expansion and harvesting the cells
It is critical to consider how much we can expand the UC-MSCs to allow 
allogeneic “off-the-shelf ” industrial availability, because the proliferation of 
adherent cells needs a large surface area. The conventional method uses multi-
layered flasks, and the cells are cultured in incubators installed in cleanrooms. 
These multilayer flasks can consistently support the expansion of UC-MSCs, and 
the state of cell confluence can be examined under the microscope. However, 
this method requires the considerable involvement of operators because the 
processes of seeding, refreshment, passage, and harvest require individual and 
manual works. Several companies have introduced the spinner bioreactor with 
a microcarrier made of plastic, dextran, denatured collagen-coated beads, and 
other components. The bioreactor system may reduce the number of operators 
required and may allow to reduce the clean levels of facility since it is a closed 
system. On the contrary, several critical problems of the bioreactor system exist. 
The cost of equipment is high and it is difficult to evaluate cell proliferation 
environment such as pH, lactate, and so on. When some microcarriers are torn 
off by spinner, or undigested microcarriers are residual in the final products, 
we have no ideas to remove the residual microcarriers completely. Recently, a 
plastic bag bioreactor system with a microcarrier in gentle locking was reported 
[27]. The most critical problem is that the cells produced by the flask-based 
culture method may be different from those by bioreactors. Harvesting cells on a 
large scale is still not easy. Recently, filter-based cell concentration and washing 
systems were introduced (https://www.kaneka.co.jp/en/business/healthcare/
med_006.html, KANEKA, Japan). Automatic cell packaging may be also 
required in large-scale expansion.
The academic culture level such as IMSUT CORD is at small to middle scale. 
Only the company may have the ability to expand the cells at extra-large scale and 
maintain to control and supply the cell product for clinic constantly.
4.4 Long-term cryopreservation
Master and product cells of UC-MSCs for clinical use are usually required for 
long-term cryopreservation, together with records on the donor infant and the 
mother. There are several cryoprotectants for long-term cryopreservation. The most 
popular cryoprotectant consists of 5–10% dimethyl sulfoxide with human albumin. 
Recently, serum-free cryoprotectants, described in Section 4.1, have been com-
mercialized and are thought to be more ideal compared to those containing human-
derived serum. In addition to cryoprotectants, it is important to build an adequate 
record preservation system. Those who manage the long-term cryopreservation 
should preserve the records that include the documentation relating to the collection 
including donors, processing, results of quality tests, and instruments directly related 
to the products. The kinds of records and the length to be preserved are in accordance 
with the bank policies and standards and the corresponding domestic laws and 
regulations. It is necessary to discuss how long we should or we can cryopreserve CB 
and UC tissue, UC master cells, and product cells, in the technical and ethical aspects. 
In the technical aspect, the cell-preserving vessel to accommodate the cell suspension 
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for long-term freezing should be durable in a liquid nitrogen. In the ethical aspect, we 
do not expect whether the babies can recapture their ownership of CB and UC even 
though their mother waived the ownership of them, when they grow up to be adult.
4.5 Quality and safety assurance of UC-MSCs
The Mesenchymal and Tissue Stem Cell Committee of the International Society 
for Cellular Therapy proposed the minimal criteria for defining human MSCs 
[28, 29]. First, MSCs must be plastic-adherent when maintained in standard culture 
conditions. Second, MSC must express CD105, CD73, and CD90 but not CD45, 
CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR surface molecules. Third, 
MSCs must differentiate into adipocytes, chondroblasts, and osteoblasts in vitro 
[30–32]. Immunosuppressive effects have now become the most popular property 
of MSCs for potential clinical use [12]. Defect in HLA-class II expression with nega-
tive CD80 and CD86in UC-MSCs even in the presence of inflammatory cytokines 
such as IFN-γ can theoretically rescue them from immune recognition by CD4+ T 
cells [33]. MSCs can also inhibit proliferation of and cytokine secretion by immune 
cells, as well as alter subtypes of macrophage from M1 to M2 in vitro [34–37]. 
This immunomodulation is linked mainly to soluble factors such as indoleamine 
2,3-dioxygenase (IDO), PGE2, and HLA-G5 [38], hepatocyte growth factor, and 
transforming growth factor-β1 released from MSCs [39]. Further quality tests are 
dependent on clinical applications and characteristics of MSCs.
The safety tests required differ according to the risks of clinical applications. 
For example, the tests of CB banking for hematopoietic stem cell transplantation 
are different from those of UC-MSCs. Donor-recipient relation of the former is 
one-to-one, and the risk is limited to one patient. On the other hand, that relation-
ship of the latter, as UC-MSCs master cells and product cells, is one-to-many, so 
hundreds of patients may suffer health injuries by one donor. Thus, the vials of 
UC-MSCs are tested thoroughly at a designated time not only known viruses but 
also unknown viruses. Those tests should follow the local, national or international 
applicable laws and regulations. More precise safety tests for CB and UC shall be 
described elsewhere for the respective products for clinical application.
5. Standards and guidance for CB and UC from collection to release
There are international standards/guidance for CB collection, banking, and 
release of hematopoietic stem cell transplantation, such as the Foundation for the 
Accreditation of Cellular Therapy (FACT)/NETCORD [40], American associa-
tion of Blood Banks (AABB), US Food and Drug Administration (FDA) shown in 
Table 1, and local standards or regulations under the applicable laws in respective 
countries. A CB/UC bank, facility, or individual should implement if the standard 
of practice in the community or applicable law establish additional requirements. 
International standards/guidance for biobanking process for UC collection, 
processing, culture, and release has not been settled, but collection and banking 
protocols can follow the CB banking standards and good tissue practice. Each  
CB/UC bank, facility, and individual should analyze its practices and procedures 
to determine whether additional standards apply. Compliance with the standards 
is not an exclusive means of complying with the standard of care in the industry 
or community or with local, national, or international laws or regulations [40]. 
Allogeneic public CB banks requested US FDA accreditation with FACT/NETCORD 
or AABB in the USA, while the CB banks in Europe (EU) required FACT/NetCord 
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Items Accreditation 
organization
Standards or guidance titles
Cord blood (CB) processing 
for hematopoietic stem cell 
transplantation
FACT/NETCORD
FACT/JACIE
International Standards for Cord Blood Collection, 
Banking, and Release for Administration
International Standards for Hematopoietic Cellular 
Therapy Product Collection, Processing, and 
Administration
http://www.factwebsite.org/cbstandards/
FDA in the USA Guidance for Industry: Minimally Manipulated, 
Unrelated Allogeneic Placental/Umbilical Cord 
Blood Intended for Hematopoietic Reconstitution 
for Specified Indications
Guidance for Industry and FDA Staff: 
Investigational New Drug Applications for 
Minimally Manipulated, Unrelated Allogeneic 
Placental/Umbilical Cord Blood Intended for 
Hematopoietic and Immunologic Reconstitution 
in Patients with Disorders Affecting the 
Hematopoietic System
http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/
Guidances/default.htm.
AABB Standards for Cellular Therapy Services
http://www.aabb.org/sa/Pages/Standards-Portal.
aspx
Umbilical cord-derived cells 
including mesenchymal 
stromal cells (UC-MSCs)/
somatic cell or other  
derivative cells
CB not intended for 
hematopoietic stem cell 
transplantation
FACT Common standards for Cellular Therapies
http://www.factwebsite.org/cbstandards/
FDA in the USA Good Tissue Practice 21CFR 1271.210
Current Good Tissue Practice (CGTP) and 
Additional Requirements for Manufacturers of 
Human Cells, Tissues, and Cellular and Tissue-
Based Products (HCT/Ps)
Guidance for Industry: Preclinical Assessment 
of Investigational Cellular and Gene Therapy 
Products
Guidance for FDA Reviewers and Sponsors
Content and Review of Chemistry, Manufacturing, 
and Control (CMC) Information for Human 
Somatic Cell Therapy Investigational New Drug 
Applications (INDs)
http://www.fda.gov/cber/guidelines.htm
AABB Standards for Cellular Therapy Services
http://www.aabb.org/sa/Pages/Standards-Portal.
aspx
EMA in EU Tissues and Cells Directives: Guideline on 
human cell-based medicinal products (EMEA/
CHMP/410896/2006) for ATMP
PMDA (Japan) Good Gene, Cellular, and Tissue-based Products 
Manufacturing Practice (GCTP)
Quality management system ISO ISO9001
ISO/TC276 (Draft)
https://www.iso.org/standard/62085.html
Foundation for the Accreditation of Cellular Therapy, FACT; US Food and Drug Administration, FDA; American 
Association of Blood Banks, AABB; advanced therapy medicinal products, Pharmaceutical and medical devices 
agency (PMDA). This table does not include the law defined in each country. These standards, guidance, guidelines, 
and practices are not intended to apply all cell therapies using CB and UC. The CB/UC bank carefully chooses and 
implements them for your intended products under the applicable law.
Table 1. 
Standards or guidance related to cord blood and umbilical cord-derived cells.
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with additional requirements like FACT/JACIE standards, when it is requested by 
the respective national regulation affairs. There are many private or private-public 
combined CB banks in the world, which tend to follow the AABB standards and 
have the inspection and accreditation (http://www.aabb.org/sa/facilities/cellthe-
rapy/Documents/AABB-Accredited-Cord-Blood-Facilities.pdf).
6. Special issues of CB and UC bank system for allogeneic use
The number of clinical trials using CB and UC-MSCs in the fields of immune cell 
therapies and regenerative medicine has been increasing. On the other hand, CB as 
a source of hematopoietic stem cell transplantation is less used recently, because the 
cell number is limited, the engraftment of HSC is delayed, and HLA haplo-identical 
HSCT is induced and controlled. These clinical trials are aimed uses that include 
severe acute graft-versus-host disease (GVHD) treatment, rapid engraftment of 
HSCT, and the prevention of severe acute GVHD. Clinical trials using CB- and 
UC-MSCs are summarized in Tables 2 and 3, respectively. We started a sponsor-
investigator clinical trial using UC-derived MSCs for patients with treatment-
resistant severe acute GVHD supported by the research fund of the Japan Agency for 
Medical Research and Development (AMED). Consistent supply is the critical key 
to conduct clinical trials and for marketing. For the stable supply of frozen CB and 
UC, or UC-derived MSCs, we have established a CB and UC bank, named IMSUT 
CORD, in our institute. This bank also provides CB and UC-MSCs for immunother-
apy and regenerative medicine products to hospitals and pharmaceutical companies 
shown in Figure 2. The bank also provides frozen CB, frozen UC, master cells, and 
the cells after master cells as an intermediate products requiring further processing 
or more culture in the companies.
The following are also the major points for managing CB and UC banking.
First, to build an adequate quality management system to serve the resource 
of cell therapy products, we have introduced the concept of the ISO 9001 and 
obtained its certification, and as a result, we introduced the concept of PDCA 
cycle. Second, involvements of various kinds of specialists must be considered. 
There are many procedures, such as collection, obtaining informed consent, 
application to ethics review committee, and document management. Third, 
health check and infection test of the donor’s mother are required to ensure that 
no infection is detected after window period of infections. In this process, both 
traceability and personal information protection must be satisfied. Fourth, we 
respect the right of decision to donate, rejection, or withdrawal. Donor’s mother 
should be explained the policy of the bank that the consented withdrawal time is 
set at the initiation of processing for clinical use. Although the CB and UC belong 
to the baby, we obtain informed consent from the donor’s mother as guardianship 
and ownership are asked to be transferred to the bank. Fifth, there is also the issue 
of how long the UC tissue and UC-MSCs can be cryopreserved. For example, in 
the Japanese public CB bank for HSCT, the CB is cryopreserved for 10 years as a 
clinical grade of HSC source. After this period, they are used for basic research or 
preclinical studies or discarded if they are not used for research. A cryopreserva-
tion period of 10 years for UC and UC-MSCs may be the first threshold to be 
checked. In addition, we disclose the information in website for the mothers who 
have not been explained about the new researches or new clinical trials at the 
first IC acquisition. Lastly, because unlike CB, the UC is a tissue considered as a 
part of the perinatal appendage, we must follow the tissue transport and medical 
disposal/waste regulations under the applicable laws or local rules and ethical 
standards.
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Authors Cell type Disease Patients 
number
Age (range) year Route and 
procedure of 
administration
Cell number/kg or 
body
Results Adverse events
Brunstein 
et al. [79]
CB-NC-derived Treg 
(CB from The New York 
Blood Center)
Grade II–IV 
acute GVHD
Treg: 11 61 (45–68) IV 3–100 × 106 Treg/kg aGVHD: Treg 
group 9%, control 
45% cGVHD: Treg 
0%, control 14%
No dose-limiting 
infusion adverse events
Control: 22 60 (34–69) —
Kellner 
et al. [80]
Fucosylated or non-
fucosylated UCB-Tregs
HSCT 5 IV (−1 day of 
HSCT)
1 × 106/kg No infusion reactions
Zhu et al. 
[81]
CB-MNC Chronic 
complete 
spinal cord 
injury
8 in Hong 
Kong
42.6 ± 2.7 IT (dorsal entry 
zone)
1.6–3.2 × 106 Walk 10 m, 15/20 
pts. (p = 0.001), 
no necessity 
of assistance 
for bladder 
management, 
12/20 (p = 0.001) 
and bowel 
management 
(p = 0.002)
1 neuropathic 
pain;1 subarachnoid 
hematoma and 
pneumocephalus due 
to cerebrospinal loss;1 
arachnoid hemorrhage 
I HK group,
Phase I–II 20 in 
Kunming
36.9 ± 2.4 68 AEs including 
postoperative wound 
swelling; 9 pain
Overall 5 severe AE in 
28 patients
Shah et al. 
[82]
CB-MNC-derived NK 
cells (CB from MD 
Anderson Cord Blood 
Bank)
Multiple 
myeloma 
undergoing 
autologous 
PBSCT
12 48–70 5 × 106, 1 × 107, 5 × 107 
and 1 × 108 CB-NK 
cells/kg
10 achieved VGPR 
(8 near CR) as the 
best response
No infusional toxicities 
and no GVHD
Lv et al. 
[83]
CB-MSC + UC-MSCs Autism 14 CB-MNC
9 CB-MNC 
and 
UC-MSCs
14 no cells 
therapy
CB-MNC: 7.08 
(3.29–12.01) 
CB-MNC + UC-MSCs: 
6.51 (3.98–9.83)
Control: 5.02 (3.51–10.02)
IV Proximately 2 × 106/
kg CB-MNCs
1 × 106/kg of 
UC-MSCs
4 times in 5–7 day
Improvement 
of CARS, ABC 
scores, and 
CGI evaluation 
at 24 weeks in 
CB-MNCs with 
UC-MSCs
No treatment-related 
and no severe adverse 
effects
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number
Age (range) year Route and 
procedure of 
administration
Cell number/kg or 
body
Results Adverse events
Dolstra 
et al. [84]
CB-CD34-derived NK 
cells (CB from Cord 
Blood Bank Nijmegen)
AML in old 
patients
10 68–76 IV 3 and 30 × 106/kg NK cell maturation 
in vivo, MRD 
become negative 
in 2/4 with MRD 
before IV
No GVHD, no toxicity
Park et al. 
[85]
CB-derived MSCs Rheumatoid 
arthritis
9 57.4 ± 10.0 IV 2.5 × 107, 5 × 107, or 
1 × 108
DAS2/-ESR 
decreased, 
inflammatory 
cytokine levels are 
reduced
No DLT, no major 
toxicity
Laskowitz 
et al. [86]
CB-NC (CB from 
Carolinas Cord Blood 
Bank or MD Anderson 
Cord Blood Bank)
Cerebral 
stroke
10 65.5 (45–79) IV on 3–9 days 
poststroke
Cell dose 1.54 
(0.84–3.34) × 107/
kg, CD34+ 2.03 
(0.10–6.80) × 105/kg
All improved by at 
least one grade in 
Modified Rankin 
Score
AE tolerated no serious 
AE
Huang et al. 
[87]
CB-MSCs Cerebral palsy 
(age: 3–12)
27 
(CB-MSCs)
CB-MSCs: 7 (3–12) IV 27:4 CB-MSCs 
IV at 5 × 107 with 
basic rehabilitation 
treatment
Significant 
improved of 
GMFM-88 
evaluation
No serious AE
27 (control) Control: 7 (3–12)
Kim et al. 
[88]
CB-MSCs Moderate-to-
severe atopic 
dermatitis
34 (7 in phase 
I, 27 in phase 
IIa)
29.07 ± 2.03 (n = 14) SC 2.5 × 107 Improved atopic 
dermatitis scores, 
pruritus score, 
serum IgE and 
eosinophil number
No serious AE
28.08 ± 1.07 (n = 11) 5.0 × 107
AE, adverse event; AML, acute myeloid leukemia; CB, cord blood; UC, umbilical cord; MSCs, mesenchymal stromal cells; MNCs, mononuclear cells; NK cells, natural killer cells; Treg, regulatory T cells; 
GVHD, graft-versus-host disease; PBSCT, peripheral blood stem cell transplantation; IV, intravenous injection; SC, subcutaneous injection.
Table 2. 
Clinical trials using allogeneic cord blood.
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Engraftment facilitation and graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation
Wu et al. 
[41]
Severe steroid-
resistant aGVHD
2 Pt 1:4 IV Pt 1: 3.3, 7.2, 8.0 × 106/
kg
3 Improved No
Pt 2:6 IV Pt 2: 4.1 × 106/kg 1
Si et al. 
[42]
Severe aplastic 
anemia
37 5 IV (7–10 days 
after HSCT)
1 × 106/kg 1 aGVHD II–IV; 17 of 
37 (45.9%)
No
(0.75–11.58) cGVHD, 7 of 37 
(18.9%)
Wu et al. 
[43]
Refractory/
relapsed 
hematologic 
malignancy
50 26 (9–58) IV (4 h before 
haploidentical 
HSCT)
5 × 105/kg 1 aGVHD II–IV, 12 of 
50 (24.0%) cGVHD, 
17 of 45 (37.7%) (3 
extended)
No
Wu et al. 
[44]
Severe AA 21 18 (4–31) IV (4 h before 
HSCT)
5 × 105/kg 1 aGVHD II-IV;12 of 
21 (57.1%) 3 of 9 
extended cGVHD
No
Fu et al. 
[45]
Refractory severe 
AA
5 15.2 (9–22) IV (2 days after 
PBSCT)
1 × 106/kg 1 No severe aGVHD 
or cGVHD
No
Gao et al. 
[46]
Prophylaxis of 
chronic GVHD 
after HLA-
haploidentical 
stem cell 
transplantation
62 Age < 8, 15 
pts.; 18–40, 
39; >40, 8
IV 3 × 107 cells Until 
cGVHD 
occurred, 
leukemia 
relapsed, 
or 4 cycles
cGVHD at 2 yr.: 
MSCs group 27.4%, 
control 49.0% 
(P = .021). Severe 
lung cGVHD: MSCs 
group 0, control 7 
(P = .047)
No
Zhu et al. 
[47]
High-risk acute 
leukemia
25 11.2 (4–17) IV (before 
haploidentical 
HSCT)
Median 1.14 × 106/kg 
(1.03–1.39 × 106/kg)
4 (over 
7 days 
intervals)
aGVHDI, 8 
of 25 (32.0%) 
cytomegalovirus 
viremia, 23 of 25 
(92.0%)
No
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Pan et al. 
[48]
Extensive bone 
marrow necrosis 
of a chronic 
myeloid leukemia 
patient
1 10 iBM iBM: 2 × 107/kg 1 BM recovered No
IV IV: 2 pp. × 106/kg
Neurogenic injuries
Wang 
et al. [49]
Traumatic brain 
injury
20 27.5 (5–48) Intrathecal (IT) 1 × 107 4 (5–7 days 
intervals)
Motor functional 
recovery after 6 
months
No
Jin et al. 
[50]
Hereditary 
spinocerebellar 
ataxia
16 39.9 (21–56) IV + intrathecal IV; 4 × 107 4 (over 
7 days 
interval)
Motor functional 
recovery after 
6 months
No
IT; 2 × 107 cells
Wang 
et al. [51]
Cerebral palsy 16 (8 twins) 6.29 (3–12) IT 1–1.5 × 107 cells 4 (3–5 days 
intervals)
Motor functional 
recovery after 1 and 
6 months
No
Diabetes mellitus
Guan 
et al. [52]
DM (type 2) 6 40.5 (27–51) IV 1 × 106/kg 2 (2 weeks 
interval)
Insulin-independent 
for 25–43 Mo, 3 dose 
reduction of insulin, 
others
No
Hu et al. 
[53]
DM (type 1) 15 17.6 IV 2.6 ± 1.2 × 107/kg 2 (4 weeks 
interval)
HbA1c and 
C-peptide 
improvement in 
MSCs group
No
Cai et al. 
[54]
DM (type 1) 21 18–29 (5–28) 
at onset
Supraselective 
pancreatic artery 
cannulation
1.1 × 106/kg, with 
autologous BM-MNC
1 Moderate 
improvement of 
metabolic measures
1 transient 
abdominal pain
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Kong 
et al. [55]
DM (type 2) 18 IV 1 × 106/kg Day 0 
and until 
Day 90 if 
effective
FBS reduced plasma 
C-peptide and 
regulatory T cells 
increased
4/18: slight fever
Heart and angioplasty
Cai et al. 
[56]
Avascular 
necrosis of the 
femoral head
30 41.6 (19–63) Femoral head 
artery (co 
transplant with 
autologous BM)
Autologous 
BM-BM-MNCs, 
60.7 ± 11.5 × 106/kg
UC-MSCs, 1 × 106/kg
1 Improved No
Can et al. 
[57]
Myocardial 
ischemia
39 30–80 Intracoronary 2 × 107/kg 1 Ongoing No
Zhao et al. 
[58]
Severe systolic 
heart failure
30 52.9 (20–79) Intracoronary Unknown 1 Cardiac remodeling 
and function 
improved with 
reduced mortality 
rate
No
Li et al. 
[59]
Coronary chronic 
total occlusion
15 Unknown Intracoronary 3 × 106/4 × 106/5 × 106/
kg
1 Infarcted size 
reduced with 
improved left 
ventricular EF
No
Musialek 
et al. [60]
Acute myocardial 
infarction
10 55.6 (32–65) Intracoronary 3 × 107/body 1 Feasible and 
procedural safe 
as off-the-shelf 
cellular therapy
Transient fever 
(38.9°C)
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Bartolucci 
[61]
Heart failure 15 57.33 ± 10.05 IV 1 × 106 cells/kg 1 Significant 
improvements 
in LVEF, NYHA 
functional class, 
Minnesota Living 
with Heart Failure 
Questionnaire
No
Liver
Xue et al. 
[62]
Decompensated 
liver cirrhosis
50 Unknown Intrahepatic 
artery
3 × 107/body 1 Increase of serum 
albumin
No
Wang 
et al. [63]
Primary biliary 
cirrhosis
7 49 (33–58) IV 5 × 105/kg at 4 weeks 
interval
3 ALP and γ-GTP No
Shi et al. 
[64]
Prevention 
of acute liver 
allograft rejection
14 (13, single dose, 
1 multiple dose)
57 ± 12 IV 1 × 106 cells Single (13 
pts), 3 
times every 
4w (1 pt)
Decreases of 
ALT, AST, 
T-BIL Histologic 
improvements, 
MSCs 6, control 0.
No
Liang 
et al. [65]
Liver cirrhosis 
caused by 
autoimmune 
diseases
23 (2 CB-MSC, 1 
BM MSC)
53.4 (35–70) IV 1 × 106 cells/kg 1 Not statistically 
significant 
improvement
2, fever; 3, mild 
fidgetiness, 
suffered from 
insomnia
Zhang 
et al. [66]
Ischemic-type 
biliary lesions 
following liver 
transplantation
12 47.3 ± 10.1 IV 1 × 106 cells/kg 6 (1, 2, 
4, 8, 12, 
16 weeks)
Significantly 
decreased need 
for interventional 
therapies. 1-, 2-yr 
graft survival rates: 
MSCs group (100%, 
83.3%), control 
group (72.9%, 
68.6%)
No
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Xu et al. 
[67]
Hepatitis B 
virus-related 
acute-on-chronic 
liver failure
30:UC-MSC UC-MSC: 
40.67 ± 9.89
IV 105 cells/kg UC-MSC, 
once a 
week, 4 
times
No significant 
improvement 
of short-term 
prognosis
Fever, UC-MSC 
11 pts., 
PE + UC-MSC 
6 pts
20, 
UC-MSC + plasma 
exchange
UC-MSC/
plasma 
exchange, 
42.00 ± 6.55
IV UC-MSC/
PE: first 2 
UC-MSC: 
2nd day 
after 1st, 
3rd PE 
treatments
Gastrointestinal tract
Zhang 
et al. [68]
Crohn’s disease 41 32.7 (20–41) IV 1 × 106 cells/kg Once a 
week, four 
times
Decreases of CDAI, 
HBI, corticosteroid 
dosage
Fever 4, upper 
respiratory tract 
infection, 7
Hu et al. 
[69]
Ulcerative colitis 34 42.9 ± 23.1 IV then IA 0.5 × 106 cells/kg 2, 7 days Decreases of 
median Mayo score, 
histology score. 
Improvement of 
IBDQ scores
No
Skin
Hashemi 
et al. [70]
Chronic skin ulcer 5 30–60 Covered by 
acellular 
amniotic 
membrane 
seeded with 
WJSCs
About 2 × 106 cells were 
seeded
Epithelial 
surface of 
acellular 
amniotic 
membrane
Significantly 
decreased wound 
healing time, 
wound size. 
Significantly 
declined wound 
size after 6, 9 days
Not stated
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Kidney
Sun et al. 
[71]
Prevention of 
delayed graft 
function and 
acute rejection 
in renal 
transplantation
21 41.0 ± 11.5 IV 2 × 106 cells/kg (before 
transplantation), 
5 × 106 (during 
surgery)
← No significant 
improvement
No
Deng 
et al. [72]
Lupus nephritis 12 MSC, 6 placebo 29 ± 10 IV 1 × 108 cells 2 times 
1 wk. 
interval
Not statistically 
significant 
improvement
1: leucopenia, 
pneumonia, 
subcutaneous 
abscess, 1: severe 
pneumonia
Autoimmune diseases
Wang 
et al. [73]
Active and 
refractory SLE
40 17–54 IV 1 × 106 cells/kg on day 
0 and 7
2 MCR (13 of 40, 
32.5%), PCR (11 
of 40, 27.5%) 
during 12 months, 
although several 
patients relapse 
after 6 months
No
Wang 
et al. [74]
RA 136 46.1 IV 4 × 107 cells, 2nd in 
3 months later
1 (n = 112) Decreases of 
serum TNF-α, 
IL-6, increase 
of regulatory T 
cells. Significant 
remission for 3–6 
months
Mild fever 
(<38.5°C) 
without 
treatment at 
injection, 6 
patients
2 (n = 24)
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Riordan 
et al. [75]
Multiple sclerosis 20 41.2 (24–55) IV 2 × 107 UC-MSC 7 
(1–4 days)
Significant 
improvements of 
various symptoms. 
Inactive lesions 
by MRI in 15/18 
patients. (83.3%) 
after 1 year
Headache, fatigue
Others
He et al. 
[76]
Severe sepsis 15 (3 cohorts) 56 (25–72) IV 1 × 106 cells/kg 1 System clinical 
outcomes are not 
changed
No
2 × 106 cells/kg
3 × 106 cells/kg
Cao et al. 
[77]
Recurrent 
intrauterine 
adhesions
27 35.1 ± 3.8 
(27–42)
Loaded onto a 
collagen scaffold
1 × 107 1 Pregnant, 10 of 26 
patients
No
aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD; HSCT, hematopoietic stem cell transplantation; AA, aplastic anemia; BM, bone marrow; IT, intrathecal injection; AE, adverse event; AML, 
acute myeloid leukemia; CB, cord blood; UC, umbilical cord; BM, bone marrow; PE, plasma exchange; RA, rheumatoid arthritis; MSCs, mesenchymal stromal cells; DM, diabetes mellitus; FBS, fast blood 
sugar; ES, ejection fraction; IV, intravenous injection; SC, subcutaneous injection; DM, diabetes mellitus.
Table 3. 
Clinical trials using allogeneic umbilical cord-derived mesenchymal stromal cells.
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7. Private CB and UC banking for autologous and family use
Recently, there are an increasing number of private CB banks, which have initi-
ated to serve the cryopreservation of UC, i.e., private CB and UC bank. Using private 
autologous CB, clinical trials for cerebral palsy caused by hypoxic ischemic encepha-
lopathy (HIE) reported their efficacy [78], although the collection of CB is difficult 
for the baby in such a severe situation of delivery, resulting in the limited application 
entry. Recently, we obtained the proof of concept that the UC-MSCs attenuated the 
neurogenic and functional damage caused by intraventricular hemorrhage (IVH) in 
newborn model mice. Duke University implemented the clinical trial using allogeneic 
UC tissue-derived cells for the patients with HIE. Allogeneic off-the-shelf UC-MSCs 
are a promising source; however, we do not know the adverse events such as HLA anti-
body induction caused by long-term repeated injections of allogeneic cells. Therefore, 
autologous use of CB and UC is still challenged to be discussed continuously.
8. Conclusion
Although several problems still remain to be dissolved, operation of adequate 
CB and UC bank should be considered as the provider of cell source for regenerative 
and immune cell therapy, because of their prominent characteristics and convenient 
and noninvasive collection.
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